GRFS Grifols Group: Forward P/S Multiple
Grifols, S.A. leads the development of plasma-derived medicines, investing in immunoglobulin research and the fight against Alzheimer's disease. The forward P/S trend helps assess the sustainability of these strategies, while the value of 0.50 reflects the current metric. Scaling the raw material collection network reduces costs through economies of scale, while strict FDA requirements create insurmountable barriers to entry for new players.
Financial and market metric breakdowns for Grifols Biemat (GRFS)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt and liquidity details:
- business earnings and investment ratios data:
GRFS - Final Profit|Expected Profit Grifols, S.A.|GRFS - Business Payback Period|Projected Price to Earnings Grifols Group|GRFS - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Grifols Biemat|GRFS - Operating profit EBITDA|Net earnings per share for the last 12 months Grifols|GRFS - Net earnings per share for the last four quarters|Quarterly EPS earnings growth grifols.com|GRFS - Net earnings per share change in current year|Net earnings per share growth forecast for next year Grifols, S.A.
- company sales and revenue statistics:
Initial company analysis:GRFS (Grifols)
The complex plasma collection infrastructure provides Grifols, S.A. (GRFS) with high market defensibility, ensuring a stable cash flow from specialized pharmaceuticals. The forward P/S multiple compares market capitalization with expected revenue, determining whether current quotes are justified by future sales volumes or are overvalued relative to the business's fundamental growth rates.
Who Grifols, S.A. competes with
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Projected Price to Revenue ADMA Corp (ADMA)|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|immunovant.com - Forward Price to Sales|KNSA (Kiniksa) - Forward P/S Multiple|Adaptive Biotech (ADPT) - Market Cap to Expected Sales Ratio|Forward P/S Multiple CLDX|AUPH: Future Price to Revenue|Price-to-Projected Revenue Ratio BioCryst BCRX|veratx.com (VERA) - Market Cap to Future Revenue Ratio|DNTH - Price-to-Projected Revenue Ratio|PHVS: Price-to-Projected Revenue Ratio|AbCellera Biologics Inc (ABCL) - Price-to-Projected Revenue Ratio|TRML - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PGEN|PHAR: Forward Price to Sales|Price-to-Projected Revenue Ratio Nektar Therapeutics Inc. (NKTR)|Market Cap to Expected Sales Ratio Upstream Bio, Inc.|Zenas Biopharma, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Immunome Bio (IMNM)|Gossamer Bio, Inc. - Forward P/S Multiple|KALV - Forward P/S Multiple|SEPN (Septerna) - Forward Price-to-Revenue Multiple|PVLA - Market Cap to Expected Sales Ratio|SVRA (Savara Corp) - Forward P/S Multiple|RIGL - Projected Price to Revenue|Price-to-Projected Revenue Ratio AnaptysBio, Inc. (ANAB)|ATXS (astriatx.com) - Forward Price to Sales|Forward P/S Multiple ENGN (enGene)|RAPT (RAPT Therapeutics Inc.) - Future Price to Revenue|JBIO - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Aclaris Therapeutics, Inc ACRS|Kyverna Therapeutics (KYTX) - Price-to-Projected Revenue Ratio|Future Price to Revenue TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - Forward P/S Multiple|VTYX: Forward Price to Sales|Forward P/S Multiple THTX|Forward P/S Multiple Avalo Therapeutics Inc (AVTX)|Price-to-Projected Revenue Ratio Eledon Pharmaceuticals ELDN|Forward Price to Sales AGEN|CLYM - Price-to-Projected Revenue Ratio|Zura Bio Ltd (ZURA) - Forward Price-to-Revenue Multiple|ATYR: Forward P/S Multiple|Adagene Inc. (ADAG) - Forward P/S Multiple|Forward Price-to-Revenue Multiple IMA|STTK: Forward Price to Sales|Forward P/S Multiple EQ|Market Cap to Expected Sales Ratio connectbiopharm.com|Price-to-Projected Revenue Ratio Immunic IMUX|ATRA - Forward Price-to-Revenue Multiple|IFRX - Price-to-Projected Revenue Ratio|x4pharma.com (XFOR) - Forward Price-to-Revenue Multiple|ACET (adicetbio.com) - Forward Price-to-Revenue Multiple|Celularity (CELU) - Forward P/S Multiple|Price-to-Projected Revenue Ratio INmune Bio Corp|Market Cap to Projected Revenue BRNS (Barinthus Biotherapeutics Corp)|Forward P/S Multiple KZR|SABS - Market Cap to Future Revenue Ratio|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Projected Price to Revenue Enlivex Therapeutics Ltd|QTTB - Price-to-Projected Revenue Ratio|Forward Price to Sales GOVX (GeoVax Corp)|EDSA: Forward P/S Multiple|IBIO - Market Cap to Expected Sales Ratio|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|XTL Biopharmaceuticals Ltd - Future Price to Revenue|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|HCWB - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM ImmunoTech, Inc. - Price-to-Projected Revenue Ratio|ADTX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio GRI Bio Inc GRI|XRTX (XORTX) - Forward Price-to-Revenue Multiple|Vyome Therapeutics - Forward Price to Sales|Price-to-Projected Revenue Ratio Revelation Biosciences|indaptusrx.com (INDP) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|Market Cap to Expected Sales Ratio calcimedica.com|Forward P/S Multiple AFMD (Affimed N.V.)|Forward P/S Multiple Allakos Inc ALLK|HOOK: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|ITOS: Forward P/S Multiple|Projected Price to Revenue Ocean Biomedical Inc OCEA|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|THRD: Forward Price to Sales
